Development of the SRK/T intraocular lens implant power calculation formula.

A new implant power calculation formula (SRK/T) was developed using the nonlinear terms of the theoretical formulas as its foundation but empirical regression methodology for optimization. Postoperative anterior chamber depth prediction, retinal thickness axial length correction, and corneal refractive index were systematically and interactively optimized using an iterative process on five data sets consisting of 1,677 posterior chamber lens cases. The new SRK/T formula performed slightly better than the Holladay, SRK II, Binkhorst, and Hoffer formulas, which was the expected result as any formula performs superiorly with the data from which it was derived. Comparative accuracy of this formula upon independent data sets is addressed in a follow-up report. The formula derived provides a primarily theoretical approach under the SRK umbrella of formulas and has the added advantage of being calculable using either SRK A-constants that have been empirically derived over the last nine years or using anterior chamber depth estimates.

Comparison of the SRK/T formula and other theoretical and regression formulas.

We compared the predictive accuracy of the SRK/T formula to the SRK II, Binkhorst II, Hoffer, and Holladay formulas in seven series of cases totaling 1,050 eyes. In the combined group, the SRK/T and Holladay formulas performed only slightly better than the other formulas. In short eyes (less than 22 mm), all formulas performed well, with the SRK/T, SRK II, and Holladay formulas performing marginally better. In moderately long eyes (greater than 24.5 mm, less than or equal to 27 mm), the Hoffer and Binkhorst II formulas had a greater proportion of cases with greater than 2 diopters (D) of error and the SRK/T and Holladay were again marginally better. In the very long eyes (greater than 27 mm and less than or equal to 28.4 mm), there were only 11 cases and all formulas performed well since none had greater than 2 D of prediction error. In an extremely long eye data set (greater than 28.4 mm), the SRK II formula clearly gave the poorest result. Eyes of this length occurred in only 0.1% of cases in our unselected series. Results support the contention that the present second and third generation IOL power formulas give fairly equivalent accuracy. Other factors, such as availability, ease of use, and ability to tailor or individualize, become major considerations.

The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation.

Ketorolac tromethamine solution 0.5% (1 drop 3 times daily) was more effective than the placebo vehicle solution in suppressing postoperative anterior ocular inflammation after extracapsular cataract extraction (ECCE) and intraocular lens (IOL) implantation in this multicenter, double-masked, randomized study. Four of 60 ketorolac-treated patients compared with 25 of 58 placebo-treated patients required supplemental corticosteroid therapy to suppress inflammation in the postoperative period which was statistically significant (P less than 0.001). Even though these supplemental steroid-treated patients were kept in the analysis, the placebo-treated group showed more evidence of anterior ocular inflammation as measured by anterior segment fluorophotometry. This was consistent with slit-lamp observations of increased anterior ocular inflammation. This study supported previous studies that suggested ketorolac tromethamine ophthalmic solution 0.5% was effective and safe as a nonsteroidal anti-inflammatory agent for topical use after ECCE and IOL implantation.